Poor diet and lifestyle contribute to male pattern baldness. Treatments like Minoxidil, dietary changes, and lifestyle adjustments may help slow hair loss.
The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.
A user increased their dutasteride dosage from 0.5mg to 1mg daily, resulting in a rise in DHT levels from 148 pg/mL to 281 pg/mL, and is considering switching back to finasteride due to continued hair loss. Replies suggest retesting and emphasize the importance of bloodwork before starting treatments.
Someone who is starting to experience hair loss and is considering multiple treatments, such as minoxidil, finasteride, dutasteride, and a hair transplant, to manage it. Replies provide advice on how to approach these treatments safely and effectively.
A 27-year-old woman with androgenic alopecia is losing hair despite using oral minoxidil and spironolactone, and is considering dutasteride. She is exploring causes like stress and medication side effects, planning tests, and considering treatment changes.
A user shared their 9-month post-hair transplant results with 4600 grafts, using only Nourkin hair vitamins, Vitamin D, and B12, and expressed satisfaction. The replies debated the necessity of medications like finasteride and minoxidil for maintaining hair health.
A user shared that while finasteride improved their hair, it didn't solve all their insecurities, suggesting that self-acceptance is key. Others in the conversation expressed varying opinions, with some feeling that finasteride significantly boosted their confidence and quality of life, while others acknowledged it as a solution to hair loss but not a cure-all for other personal issues.
The user is addressing hair loss with scalp botox, scalp massage, nizoral shampoo, various vitamins and supplements, and natural nitric oxide boosters like citrulline malate and beetroot powder. They are also considering a mouthpiece to reduce snoring and improve sleep.
Diet can influence hair health, but male pattern baldness (MPB) is primarily genetic. Treatments discussed include Minoxidil, finasteride, and RU58841.
Quitting vaping significantly reduced hair loss for a user who was a heavy vaper and also taking finasteride. Some participants suggest nicotine's vasoconstrictive properties may worsen hair loss, while others share personal anecdotes of hair improvement after quitting smoking or vaping.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
RU and Pyri block androgenreceptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.
Fluridil may decrease the number of androgenreceptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
Dutasteride may inhibit androgenreceptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.
Researching and developing an effective local antagonist to block the androgenreceptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgenreceptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
The conversation discusses androgenreceptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
The post is about whether there is any additional benefit to using alfatradiol or other estrogen treatments for hair loss if someone is already using finasteride, dutasteride, or an androgenreceptor inhibitor like RU58841, pyrithione zinc, or fluridil.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgenreceptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
Pyrilutamide and RU58841 are androgenreceptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgenreceptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
The post discusses using 2% ketoconazole shampoo as a competitive androgenreceptor antagonist for hair loss, applied for 1.5 hours daily. The user questions its effectiveness and potential benefits compared to finasteride and minoxidil.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgenreceptor degrader for hair loss, and whether it can fully degrade androgenreceptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
Hopeful treatments for hair loss, including Verteporfin, AndrogenReceptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
A user is experiencing continued hair loss despite using 0.5mg dutasteride and 2.5mg minoxidil, and is seeking advice on why the treatments aren't working and how to address potential androgenreceptor sensitivity. Replies suggest getting tested and considering scalp micropigmentation (SMP).
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgenreceptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgenreceptor antagonist.
The conversation discusses how Caucasian men are more likely to experience hair loss due to genetic predisposition, with factors like the androgenreceptor on the X chromosome playing a significant role. The user also expresses confusion about the evolutionary reasons for hair loss, especially in colder climates where it would seem beneficial to retain hair for warmth.